Teva Pharmaceutical Industries (TEVA) Stock Forecast, Price & News

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last twelve months. There are currently 3 sell ratings, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TEVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares.
View TEVA analyst ratings or view top-rated stocks.

10 Wall Street analysts have issued 1 year target prices for Teva Pharmaceutical Industries' shares. Their TEVA share price forecasts range from $7.00 to $14.00. On average, they predict the company's share price to reach $10.67 in the next year. This suggests a possible upside of 44.5% from the stock's current price.
View analysts price targets for TEVA or view top-rated stocks among Wall Street analysts.

Teva Pharmaceutical Industries' stock was trading at $9.12 at the beginning of 2023. Since then, TEVA shares have decreased by 19.1% and is now trading at $7.38.
View the best growth stocks for 2023 here.

Teva Pharmaceutical Industries saw a decline in short interest in April. As of April 30th, there was short interest totaling 12,730,000 shares, a decline of 16.6% from the April 15th total of 15,260,000 shares. Based on an average trading volume of 8,860,000 shares, the short-interest ratio is presently 1.4 days.
View Teva Pharmaceutical Industries' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 25th 2023.
View our TEVA earnings forecast.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced its quarterly earnings data on Wednesday, May, 10th. The company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.55 by $0.18. The company earned $3.66 billion during the quarter, compared to analyst estimates of $3.60 billion. Teva Pharmaceutical Industries had a positive trailing twelve-month return on equity of 27.58% and a negative net margin of 10.73%.

ETFs with the largest weight of Teva Pharmaceutical Industries (NYSE:TEVA) stock in their portfolio include iShares MSCI Israel ETF (EIS), VanEck Israel ETF (ISRA), VanEck Pharmaceutical ETF (PPH), ARK Israel Innovative Technology ETF (IZRL), Affinity World Leaders Equity ETF (WLDR), iShares MSCI Intl Value Factor ETF (IVLU) and Goldman Sachs ActiveBeta International Equity ETF (GSIE).iShares MSCI EAFE Value ETF (EFV).

Teva Pharmaceutical Industries issued an update on its FY 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share guidance of $2.25-$2.55 for the period, compared to the consensus estimate of $2.40. The company issued revenue guidance of $14.80 billion-$15.40 billion, compared to the consensus revenue estimate of $15.06 billion.

158 employees have rated Teva Pharmaceutical Industries Chief Executive Officer Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Teva Pharmaceutical Industries' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.62%), Migdal Insurance & Financial Holdings Ltd. (2.10%), Harel Insurance Investments & Financial Services Ltd. (2.10%), State Street Corp (1.76%), Clal Insurance Enterprises Holdings Ltd (1.70%) and Exor Capital LLP (1.54%). Insiders that own company stock include David Matthew Stark, Eli Shani, Eliyahu Sharon Kalif, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Pharmaceutical Co Ltd Takeda, Richard Daniell, Rosemary A Crane and Sven Dethlefs.
View institutional ownership trends.

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TEVA stock can currently be purchased for approximately $7.38.

Teva Pharmaceutical Industries (NYSE:TEVA) has a market capitalization of $8.27 billion and generates $14.93 billion in revenue each year. The company earns $-2,353,000,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis.

The company employs 36,826 workers across the globe.

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The official website for the company is www.tevapharm.com. The company can be reached via phone at (723) 914-8213, via email at kevin.mannix@tevapharm.com, or via fax at 972-3923-4050.